Related Experiment Video
Updated: Apr 5, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Neuroprotective therapies: Preclinical reproducibility is only part of the problem
1Toronto Western Hospital Research Institute, Toronto, Ontario M5T 2S8, Canada. Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Institute of Medical Science, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Department of Surgery, University of Toronto, Toronto, Ontario M5S 1A8, Canada. mike.tymianski@uhn.ca.
Abstract:
Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).
